BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/9/2022 7:17:56 AM | Browse: 260 | Download: 431
 |
Received |
|
2022-01-22 13:02 |
|
Peer-Review Started |
|
2022-01-22 13:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-16 01:36 |
|
Revised |
|
2022-03-21 14:27 |
|
Second Decision |
|
2022-04-06 02:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-04-09 18:27 |
|
Articles in Press |
|
2022-04-09 18:27 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-11 12:24 |
|
Publish the Manuscript Online |
|
2022-06-09 07:17 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fei Xu, Meng-Ling Xia, Hui-Yun Pan, Jiong-Wei Pan and Yi-Hong Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yi-Hong Shen, MD, Chief Doctor, Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. drsyh@zju.edu.cn |
| Key Words |
Next-generation sequencing; DelE709_T710insD; Non-small-cell lung cancer; Dacomitinib; Uncommon EGFR mutation; Case report |
| Core Tip |
DelE709_T710insD is an extremely rare complex in-frame deletion mutation in exon 18 and accounts for only 0.11% of epidermal growth factor receptor mutations. The development of next-generation sequencing enabled the more identification of rare variants. Our case is the first report describing the clinical efficacy of dacomitinib for delE709_T710insD and achieved a progression-free survival of 7.0 mo. More patients with the rare variants may benefit from dacomitinib targeted therapy based on our study. |
| Publish Date |
2022-06-09 07:17 |
| Citation |
Xu F, Xia ML, Pan HY, Pan JW, Shen YH. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report. World J Clin Cases 2022; 10(17): 5916-5922 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i17/5916.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i17.5916 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
